Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results.

PURPOSE To prospectively compare clinical breast examination (CBE), mammography, ultrasonography (US), and contrast material-enhanced magnetic resonance (MR) imaging for screening women at genetic-familial high risk for breast cancer and report interim results, with pathologic findings as standard. MATERIALS AND METHODS Institutional review board of each center approved the research; informed written consent was obtained. CBE, mammography, US, and MR imaging were performed for yearly screening of BRCA1 or BRCA2 mutation carriers, first-degree relatives of BRCA1 or BRCA2 mutation carriers, or women enrolled because of a strong family history of breast or ovarian cancer (three or more events in first- or second-degree relatives in either maternal or paternal line; these included breast cancer in women younger than 60 years, ovarian cancer at any age, and male breast cancer at any age). RESULTS Two hundred seventy-eight women (mean age, 46 years +/- 12 [standard deviation]) were enrolled. Breast cancer was found in 11 of 278 women at first round and seven of 99 at second round (14 invasive, four intraductal; eight were <or=10 mm in diameter). Detection rate per year was 4.8% (18 of 377) overall; 4.3% (11 of 258) in BRCA1 or BRCA2 mutation carriers and first-degree relatives of BRCA1 or BRCA2 mutation carriers versus 5.9% (seven of 119) in women enrolled because of strong family history; and 5.3% (nine of 169) in women with previous personal breast and/or ovarian cancer versus 4.3% (nine of 208) in those without. In six (33%) of 18 patients, cancer was detected only with MR imaging. Sensitivity was as follows: CBE, 50% (95% confidence interval [CI]: 29%, 71%); mammography, 59% (95% CI: 36%, 78%); US, 65% (95% CI: 41%, 83%); and MR imaging, 94% (95% CI: 82%, 99%). Positive predictive value was as follows: CBE, 82% (95% CI: 52%, 95%); mammography, 77% (95% CI: 50%, 92%); US, 65% (95% CI: 41%, 83%); and MR imaging, 63% (95% CI: 43%, 79%). CONCLUSION Addition of MR imaging to the screening regimen for high-risk women may enable detection of otherwise unsuspected breast cancers.

[1]  Ellen Warner,et al.  Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination , 2004, JAMA.

[2]  P. Tartter,et al.  The significance of family history for patients with carcinoma of the breast. , 1994, Journal of the American College of Surgeons.

[3]  M. Piccart,et al.  The Hamburg statement: the partnership driving the European agenda on breast cancer. , 2004, European Journal of Cancer.

[4]  A. Bowcock,et al.  Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. , 1997, The New England journal of medicine.

[5]  J. Klijn,et al.  Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[7]  G Lutterbey,et al.  Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. , 1997, Radiology.

[8]  M. Grompe,et al.  The rapid detection of unknown mutations in nucleic acids , 1993, Nature genetics.

[9]  J M Lacroix,et al.  High performance DNA sequencing, and the detection of mutations and polymorphisms, on the Clipper sequencer , 1999, Electrophoresis.

[10]  M. King,et al.  Population genetics of BRCA1 and BRCA2. , 1997, American journal of human genetics.

[11]  T. Rebbeck,et al.  Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. , 1995, JAMA.

[12]  M. Stratton.  Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases , 1997, The Lancet.

[13]  M. O’Donovan,et al.  Optimal temperature selection for mutation detection by denaturing HPLC and comparison to single-stranded conformation polymorphism and heteroduplex analysis. , 1999, Clinical chemistry.

[14]  P. Tonin,et al.  Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes? , 1997, American journal of human genetics.

[15]  L. Liberman,et al.  Breast imaging reporting and data system (BI-RADS). , 2002, Radiologic clinics of North America.

[16]  E. Grabbe,et al.  Classification of hypervascularized lesions in CE MR imaging of the breast , 2002, European Radiology.

[17]  C. Claussen,et al.  Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast. , 1997, Radiology.

[18]  F. Podo,et al.  Women with history of breast cancer excluded from screening programs: is it the right choice? , 2005, Radiology.

[19]  J. Klijn,et al.  Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1 , 1998, The Lancet.

[20]  C. Steel,et al.  Breast cancer survival in BRCA1 carriers , 1993, The Lancet.

[21]  A R Padhani,et al.  Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS) , 2005, The Lancet.

[22]  C. Heiner,et al.  New dye-labeled terminators for improved DNA sequencing patterns. , 1997, Nucleic acids research.

[23]  D Krebs,et al.  Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. , 2000, Radiology.

[24]  P. Langenberg,et al.  Breast Imaging Reporting and Data System: inter- and intraobserver variability in feature analysis and final assessment. , 2000, AJR. American journal of roentgenology.

[25]  A. Barron,et al.  Technical challenges in applying capillary electrophoresis‐single strand conformation polymorphism for routine genetic analysis , 2002, Electrophoresis.

[26]  A. Heinig,et al.  Interventional MRI of the breast: lesion localisation and biopsy , 2000, European Radiology.

[27]  C. Merritt,et al.  Toward a standardized breast ultrasound lexicon, BI-RADS: ultrasound. , 2001, Seminars in roentgenology.

[28]  J. Coebergh,et al.  Trends in incidence of and mortality from cancer in The Netherlands in the period 1989-1998. , 2003, European journal of cancer.

[29]  J O Barentsz,et al.  Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. , 2001, Journal of the National Cancer Institute.

[30]  Mitchell D Schnall,et al.  Imaging in breast cancer: Magnetic resonance imaging , 2005, Breast Cancer Research.

[31]  W. Thompson,et al.  The genetic attributable risk of breast and ovarian cancer , 1996, Cancer.

[32]  L. Norton,et al.  BRCA-associated breast cancer in young women. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Stratton,et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[34]  C. Zuiani,et al.  The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. , 2002, Journal of experimental & clinical cancer research : CR.

[35]  G. Porter,et al.  Ten years of breast screening in the Nova Scotia Breast Screening Program, 1991-2001. experience: use of an adaptable stereotactic device in the diagnosis of screening-detected abnormalities. , 2005, Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes.

[36]  L. Liberman,et al.  Probably benign lesions at breast magnetic resonance imaging , 2003, Cancer.

[37]  E. Franssen,et al.  Management of women at increased risk for breast cancer: preliminary results from a new program. , 1997, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[38]  A. Howell,et al.  Screening by mammography, women with a family history of breast cancer. , 1998, European journal of cancer.

[39]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[40]  B. Grube,et al.  MRI of occult breast carcinoma in a high-risk population , 2004 .

[41]  Elizabeth A Morris,et al.  Fast MRI-guided vacuum-assisted breast biopsy: initial experience. , 2003, AJR. American journal of roentgenology.

[42]  F. Sardanelli,et al.  Dynamic Breast Magnetic Resonance Imaging: Effect of Changing the Region of Interest on Early Enhancement Using 2D and 3D Techniques , 2004, Journal of computer assisted tomography.

[43]  Matthijs Oudkerk,et al.  First experiences in screening women at high risk for breast cancer with MR imaging , 2000, Breast Cancer Research and Treatment.

[44]  H. D. de Koning,et al.  Hereditary breast cancer growth rates and its impact on screening policy. , 2005, European journal of cancer.

[45]  E Grabbe,et al.  Breast carcinoma: effect of preoperative contrast-enhanced MR imaging on the therapeutic approach. , 1999, Radiology.

[46]  Stanton A. Glantz,et al.  Primer of biostatistics : statistical software program version 6.0 , 1981 .

[47]  A. Fausto,et al.  MR imaging of the breast: indications, established technique, and new directions , 2003, European Radiology.

[48]  H. D. de Koning,et al.  Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. , 2004, The New England journal of medicine.

[49]  P. Chappuis,et al.  Re: Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. , 2001, Journal of the National Cancer Institute.

[50]  Cancer statistics in developing countries. Report on a WHO meeting, Nagoya, Japan, 18-22 August, 1981. , 1983, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.